Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was the target of some unusual options trading on Wednesday. Traders purchased 1,247 call options on the company. This represents an increase of Infinity compared to the average daily volume of 0 call options.

Supernus Pharmaceuticals (SUPN) opened at $37.25 on Friday. The firm has a market capitalization of $1,900.00, a P/E ratio of 34.81, a P/E/G ratio of 1.57 and a beta of 1.30. Supernus Pharmaceuticals has a 52-week low of $20.33 and a 52-week high of $50.04. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.82 and a quick ratio of 1.74.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.02. The company had revenue of $80.40 million during the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. Supernus Pharmaceuticals’s revenue was up 41.5% compared to the same quarter last year. analysts anticipate that Supernus Pharmaceuticals will post 1.07 EPS for the current fiscal year.

A number of equities research analysts have recently issued reports on SUPN shares. Jefferies Group LLC restated a “buy” rating and issued a $51.00 price target on shares of Supernus Pharmaceuticals in a research report on Friday, August 4th. BidaskClub upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 17th. Stifel Nicolaus restated a “buy” rating and issued a $47.00 price target (up from $36.00) on shares of Supernus Pharmaceuticals in a research report on Tuesday, July 18th. Cantor Fitzgerald restated a “buy” rating and issued a $49.00 price target on shares of Supernus Pharmaceuticals in a research report on Tuesday, September 19th. Finally, Cowen and Company restated a “buy” rating and issued a $50.00 price target on shares of Supernus Pharmaceuticals in a research report on Thursday, September 21st. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $49.60.

In other news, insider Stefan K.F. Schwabe sold 95,000 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $46.59, for a total value of $4,426,050.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Padmanabh P. Bhatt sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $49.86, for a total value of $249,300.00. Following the completion of the sale, the senior vice president now owns 12,500 shares of the company’s stock, valued at $623,250. The disclosure for this sale can be found here. Insiders sold 153,709 shares of company stock valued at $7,223,108 over the last 90 days. Company insiders own 6.70% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Neumeier Poma Investment Counsel LLC grew its position in Supernus Pharmaceuticals by 1.6% in the second quarter. Neumeier Poma Investment Counsel LLC now owns 890,740 shares of the specialty pharmaceutical company’s stock worth $38,391,000 after acquiring an additional 14,430 shares during the period. Teachers Advisors LLC lifted its stake in Supernus Pharmaceuticals by 6.9% during the second quarter. Teachers Advisors LLC now owns 466,060 shares of the specialty pharmaceutical company’s stock worth $20,087,000 after purchasing an additional 29,939 shares in the last quarter. Sheets Smith Wealth Management acquired a new position in Supernus Pharmaceuticals during the second quarter worth $378,000. Royce & Associates LP lifted its stake in Supernus Pharmaceuticals by 22.3% during the second quarter. Royce & Associates LP now owns 159,000 shares of the specialty pharmaceutical company’s stock worth $6,853,000 after purchasing an additional 29,000 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in Supernus Pharmaceuticals by 10.7% during the first quarter. Bank of America Corp DE now owns 362,952 shares of the specialty pharmaceutical company’s stock worth $11,361,000 after purchasing an additional 35,069 shares in the last quarter. Institutional investors own 96.11% of the company’s stock.

WARNING: “Investors Buy Large Volume of Call Options on Supernus Pharmaceuticals (SUPN)” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/investors-buy-large-volume-of-call-options-on-supernus-pharmaceuticals-supn/1694644.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.